SRGN and neoplasm: Our data from this and our previous study [13] demonstrate a role of serglycin secreted by malignant cells as an inhibitor of complement activation in the tumor microenvironment that may protect tumor cells from complement attack in the early phase of disease or later during immunotherapy.